factual

Early Pompe Pill Caused Patient Weakening

Amicus's first Pompe small molecule, after four years of research and promising animal and healthy volunteer data, caused the first two adult patients to get weaker, and the company had to stop dosing and seek a clinical hold because the drug's half-life in diseased human muscle differed from healthy volunteers.

factualpending

Speaker

John Crowley

Evidence Quote

“It turns out that the half-life of the molecule in muscle in humans was different than it was in the animals and the healthy volunteers”

Source

Biotech’s Chief Evangelist— Joys of Compounding
Created: 11/18/2026, 9:59:31 AM

Your notes

Loading notes...